Since NHE3 has been linked directly to blood volume and pressure (Alexander & Grinstein, 2006), NHE3 is targeted as an avenue to treat hypertension (Linz et al, 2016); so far, this is yet to bear fruit, although an NHE3 inhibitor was awarded FDA‐approval for irritable bowel syndrome (Siddiqui & Cash, 2020). This evidence concerns the gene SLC9A3 and irritable bowel syndrome.